Therapeutic Response

PD-L1 (CPS) >= 1 status confers therapeutic sensitivity to Cisplatin in combination with Fluorouracil and Pembrolizumab in patients with Head and Neck Squamous Cell Carcinoma.

View API

Statements

Source and description

View API